阿立哌唑与氯丙嗪治疗女性精神分裂症对照研究

Comparative study between aripiprazole and chlorpromazine in the treatment of female patients with schizophrenia

目的:探讨阿立哌唑与氯丙嗪对女性精神分裂症患者的疗效及安全性。方法:对68例女性精神分裂症患者随机分为两组,分别给予阿立哌唑与氯丙嗪治疗,疗程8周。用阳性与阴性症状量表(PANSS)与副反应量表(TESS)评定疗效和不良反应。结果:两组总的疗效差异无显著性(P>0.05),但阿立哌唑起效较快;且在治疗阴性症状方面,以阿立哌唑显著较好(P<0.05)。阿立哌唑组不良反应较氯丙嗪组少,其中震颤、静坐不能、视物模糊、心动过速显著少于氯丙嗪组(P<0.05)。结论:阿立哌唑是一种安全有效的抗精神病药。

Objective：To detect the clinical efficacy and side effects of aripiprazole and chlorpromazine in the treatment of female schizophrenic patients. Methods ：68 female schizophrenic patients have been divided into aripiprazole group and chlorpromazine group randomly to treat for 8 weeks . Positive and negative syndrome scale （PANSS） and treatment emergent symptom scale （TESS） were used to evaluate the efficacy and side effects respectively. Results： There were no significant difference between two groups（ P 〉 0.05 ）. However, Aripiprazole took effect more quickly. But, Significant difference were found between two groups in the reduction rate of scale about negative symptoms （ P 〈 0.05 ）. Patients in aripiprazole group reported much fewer side effects than those in eblorpromazine group, especially in the items of tremor, skathisia, blur sight and tachycardia on TESS（ P 〈 0.05 ）. Conclusions： Aripiprazole is an effective antipsyshotic drug with fewer side effects.